title: Behavioral toxicity of anticholinesterases in primates: chronic physostigmine and soman interactions.
abstract: Dose rates for continuous infusion of physostigmine salicylate required to inhibit 30 and 60% of normal serum cholinesterase activity in rhesus monkeys were determined. The effects of continuous physostigmine infusion at these dose rates on the behavioral toxicity of daily repeated low-dose soman were determined not to be deleterious; in fact, they were slightly (and variably) protective.
authors.affiliation: Systems Research Laboratories Division of Arvin/Calspan, USAF Armstrong Laboratory, Brooks AFB, TX 78235-5000.
authors.forename: D W
authors.initials: DW
authors.lastname: Blick
authors.forename: S A
authors.initials: SA
authors.lastname: Miller
authors.forename: G C
authors.initials: GC
authors.lastname: Brown
authors.forename: M R
authors.initials: MR
authors.lastname: Murphy
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002800:Cholinesterase Inhibitors / Q000633:toxicity*; D002802:Cholinesterases / Q000097:blood; D004347:Drug Interactions; D007279:Injections, Subcutaneous; D008253:Macaca mulatta; D008297:Male; D010830:Physostigmine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000633:toxicity*; D011597:Psychomotor Performance / Q000187:drug effects; D011729:Pyridostigmine Bromide / Q000494:pharmacology; D012999:Soman / Q000037:antagonists & inhibitors / Q000633:toxicity*
chemical_list: D002800:Cholinesterase Inhibitors; D012999:Soman; D010830:Physostigmine; D002802:Cholinesterases; D011729:Pyridostigmine Bromide